Table 3. Correlation between KRAS, NRAS, and BRAF mutation status and clinicopathological features in Arab CRC patients.
| Clinicopathological features | KRAS status | NRAS status | BRAF status | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Wild type (%) | Mutant type (%) | P | Wild type (%) | Mutant type (%) | P | Wild type (%) | Mutant type (%) | P | |||
| Age (years) | 0.8 | 0.3 | 1 | ||||||||
| >50 | 28 (53.8) | 24 (46.2) | 51 (98.1) | 1 (1.9) | 50 (96.2) | 2 (3.8) | |||||
| ≤50 | 26 (56.5) | 20 (43.5) | 43 (93.5) | 3 (6.5) | 44 (95.7) | 2 (4.3) | |||||
| Sex | 0.5 | 1 | 0.6 | ||||||||
| Female | 20 (51.3) | 19 (48.7) | 38 (97.4) | 1 (2.6) | 37 (94.9) | 2 (5.1) | |||||
| Male | 35 (58.3) | 25 (41.7) | 57 (95.0) | 3 (5.0) | 58 (96.7) | 2 (3.3) | |||||
| Family history | 0.7038 | 0.3 | 1 | ||||||||
| No | 46 (53.5) | 40 (46.5) | 83 (96.5) | 3 (3.5) | 83 (96.5) | 3 (3.5) | |||||
| Yes | 3 (42.9) | 4 (57.1) | 6 (85.7) | 1 (14.3) | 7 (100.0) | – | |||||
| Personal history of FAP | 1 | 1 | 1 | ||||||||
| No | 48 (52.2) | 44 (47.8) | 88 (95.7) | 4 (4.3) | 89 (96.7) | 3 (3.3) | |||||
| Yes | 1 (100.0) | – | 1 (100.0) | – | 1 (100.0) | – | |||||
| Primary tumor site | 1 | 0.5693 | 1 | ||||||||
| Left sided | 36 (52.2) | 33 (47.8) | 65 (94.2) | 4 (5.8) | 67 (97.1) | 2 (2.9) | |||||
| Right sided | 13 (54.2) | 11 (45.8) | 24 (100.0) | – | 23 (95.8) | 1 (4.2) | |||||
| Tumor differentiation | 0.5 | 0.2 | 0.2 | ||||||||
| Well | 4 (80.0) | 1 (20.0) | 4 (80.0) | 1 (20.0) | 4 (80.0) | 1 (20.0) | |||||
| Moderate | 33 (50.0) | 33 (50.0) | 64 (97.0) | 2 (3.0) | 64 (97.0) | 2 (3.0) | |||||
| Poor | 12 (54.5) | 10 (45.5) | 21 (95.5) | 1 (4.5) | 22 (100.0) | – | |||||
| MSI | 0.09 | 1 | 0.6 | ||||||||
| High | – | 1 (100.0) | 1 (100.0) | – | 1 (100.0) | – | |||||
| Intact | 4 (100.0) | – | 4 (100.0) | – | 4 (100.0) | – | |||||
| Stable | 10 (43.5) | 13 (56.5) | 22 (95.7) | 1 (4.3) | 23 (100.0) | – | |||||
| Unknown | 20 (40.0) | 30 (60.0) | 47 (94.0) | 3 (6.0) | 47 (94.0) | – | |||||
| Histological type | 0.3 | 1 | 1 | ||||||||
| Tubular adenocarcinoma | 42 (50.6) | 41 (49.4) | 79 (95.2) | 4 (4.8) | 80 (96.4) | 3 (3.6) | |||||
| Mucinous adenocarcinoma | 7 (70.0) | 3 (30.0) | 10 (100.0) | – | 10 (100.0) | – | |||||
| TNM stage at diagnosis | 0.1 | 0.2 | 0.6 | ||||||||
| I | 1 (100.0) | – | 1 (100.0) | – | 1 (100.0) | – | |||||
| II | 1 (50.0) | 1 (50.0) | 2 (100.0) | – | 2 (100.0) | – | |||||
| III | 26 (63.4) | 15 (36.6) | 41 (100.0) | – | 39 (95.1) | – | |||||
| IV | 21 (42.9) | 28 (57.1) | 45 (91.8) | 4 (8.2) | 48 (98.0) | – | |||||
| Clinical status | 0.2 | 0.07 | 0.2 | ||||||||
| Alive | 20 (55.6) | 16 (44.4) | 36 (100.0) | – | 36 (100.0) | – | |||||
| Dead | 16 (42.1) | 22 (57.9) | 34 (89.5) | 4 (10.5) | 35 (92.1) | 3 (7.9) | |||||
| Unknown | 13 (68.4) | 6 (31.6) | 19 (100.0) | – | 19 (100.0) | – | |||||
FAP, familial adenomatous polyposis; MSI, microsatellite instability; CRC, colorectal cancer.